![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CDK7 |
Gene summary for CDK7 |
![]() |
Gene information | Species | Human | Gene symbol | CDK7 | Gene ID | 1022 |
Gene name | cyclin dependent kinase 7 | |
Gene Alias | CAK | |
Cytomap | 5q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | P50613 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1022 | CDK7 | P2_cSCC | Human | Skin | cSCC | 3.69e-03 | 2.16e-01 | -0.024 |
1022 | CDK7 | P4_cSCC | Human | Skin | cSCC | 3.74e-10 | 3.81e-01 | -0.00290000000000005 |
1022 | CDK7 | P10_cSCC | Human | Skin | cSCC | 2.29e-13 | 4.98e-01 | 0.1017 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:00987812 | Esophagus | ESCC | ncRNA transcription | 45/8552 | 56/18723 | 1.05e-07 | 1.72e-06 | 45 |
GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
GO:00000794 | Esophagus | ESCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 66/8552 | 94/18723 | 1.24e-06 | 1.53e-05 | 66 |
GO:00063673 | Esophagus | ESCC | transcription initiation from RNA polymerase II promoter | 56/8552 | 77/18723 | 1.30e-06 | 1.59e-05 | 56 |
GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
GO:00708161 | Esophagus | ESCC | phosphorylation of RNA polymerase II C-terminal domain | 12/8552 | 12/18723 | 8.21e-05 | 6.01e-04 | 12 |
GO:00093011 | Esophagus | ESCC | snRNA transcription | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
GO:00427951 | Esophagus | ESCC | snRNA transcription by RNA polymerase II | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
GO:003164720 | Oral cavity | OSCC | regulation of protein stability | 193/7305 | 298/18723 | 1.30e-19 | 1.95e-17 | 193 |
GO:005082120 | Oral cavity | OSCC | protein stabilization | 122/7305 | 191/18723 | 2.69e-12 | 1.09e-10 | 122 |
GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
GO:19040293 | Oral cavity | OSCC | regulation of cyclin-dependent protein kinase activity | 60/7305 | 98/18723 | 6.90e-06 | 7.56e-05 | 60 |
GO:00000793 | Oral cavity | OSCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 58/7305 | 94/18723 | 6.92e-06 | 7.57e-05 | 58 |
GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
GO:00063672 | Oral cavity | OSCC | transcription initiation from RNA polymerase II promoter | 46/7305 | 77/18723 | 1.82e-04 | 1.24e-03 | 46 |
GO:0009301 | Oral cavity | OSCC | snRNA transcription | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0342022 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa030222 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0342032 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0302211 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa034204 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
hsa03022 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0342011 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
hsa030221 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK7 | SNV | Missense_Mutation | c.274N>A | p.Asp92Asn | p.D92N | P50613 | protein_coding | deleterious(0.03) | possibly_damaging(0.907) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CDK7 | SNV | Missense_Mutation | c.658G>C | p.Asp220His | p.D220H | P50613 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-BH-A0DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
CDK7 | SNV | Missense_Mutation | c.715N>C | p.Asp239His | p.D239H | P50613 | protein_coding | tolerated(0.08) | benign(0.001) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
CDK7 | SNV | Missense_Mutation | novel | c.799G>A | p.Asp267Asn | p.D267N | P50613 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CDK7 | SNV | Missense_Mutation | novel | c.367C>G | p.Gln123Glu | p.Q123E | P50613 | protein_coding | tolerated(0.09) | benign(0.048) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CDK7 | SNV | Missense_Mutation | c.388N>A | p.Gln130Lys | p.Q130K | P50613 | protein_coding | tolerated(0.95) | benign(0.003) | TCGA-AA-3712-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
CDK7 | SNV | Missense_Mutation | rs866887561 | c.475N>A | p.Ala159Thr | p.A159T | P50613 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDK7 | SNV | Missense_Mutation | c.116C>T | p.Ala39Val | p.A39V | P50613 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CDK7 | SNV | Missense_Mutation | novel | c.20N>A | p.Ser7Tyr | p.S7Y | P50613 | protein_coding | deleterious(0.01) | benign(0.342) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CDK7 | SNV | Missense_Mutation | novel | c.314N>C | p.Asn105Thr | p.N105T | P50613 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | inhibitor | SNS-032 | BMS-387032 | |
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | Oxazolyl methylthiothiazole derivative 1 | |||
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL1944698 | ZOTIRACICLIB | |
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | inhibitor | SELICICLIB | SELICICLIB | |
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | SELICICLIB | SELICICLIB | ||
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL296468 | BMS-387032 | |
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102568 | ||
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | Pyrazolo-triazine derivative 2 | |||
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 387065624 | ||
1022 | CDK7 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DNA REPAIR, TRANSCRIPTION FACTOR, ENZYME | ENTRECTINIB | ENTRECTINIB |
Page: 1 2 3 4 5 6 |